Drug updated on 11/10/2023
|Injection (intravenous; 800 mg/50 mL)
| Ongoing and
- Indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
Product Monograph / Prescribing Information
|Portrazza (necitumumab) prescribing information.
|Lilly USA, LLC, Indianapolis, IN
Systematic Reviews / Meta-Analyses
|Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.
|Annals of Palliative Medicine
|Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis
|Journal of oncology pharmacy practice
|First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.
|Journal of Thoracic Disease